Table 1.
Clinical characteristics of the participants in this study: overview.
| PSP | PD | HC | ||
|---|---|---|---|---|
| N | 10 | 11 | 10 | |
| Age (years) | 65.9 ± 4.6 | 65.5 ± 12.7 | 68.3 ± 9.1 | |
| Gender (F/M) | 3/7 | 3/8 | 6/4 | |
| DD (years) | 3.9 ± 2.7 | 6.2 ± 4.7 | – | |
| H&Y | 3.9 ± 0.4 | 2.5 ± 0.4 | ||
| Wheelchair | 2/10 | 2/11 | 0/10 | |
| Real-life measurement time | 304.3 ± 114.4 s | 242.2 ± 78.5 s | 202.8 ± 35.3 s | |
| Details | ||||
| Patient ID/gender/age [years] | Onset | Exam. date | H&Y | Medication |
| PSP01/F/67 | 2004 | 08/2010 | 4 | Levodopa |
| PSP02/M/70 | 2008 | 08/2010 | 3 | Amantadine |
| PSP03/F/63 | 2007 | 08/2010 | 4 | Levodopa, Amantadine |
| PSP04/M/70 | 2007 | 08/2010 | 4 | Levodopa, Amantadine, Piribedil |
| PSP05/F/65 | 2007 | 08/2010 | 3 | Amantadine, Rotigotine |
| PSP06/M/67 | 2000 | 08/2010 | 4 | Levodopa |
| PSP07/M/62 | 2008 | 02/2011 | 4 | Levodopa |
| PSP08/M/74 | 2005 | 05/2011 | 4 | Levodopa, Amantadine |
| PSP09/M/59 | 2010 | 10/2011 | 3 | Levodopa |
| PSP10/M/62 | 2009 | 11/2011 | 3 | Levodopa |
| PD01/M/61 | 2007 | 09/2010 | 2 | Rotigotine |
| PD02/M/75 | 1995 | 09/2010 | 3 | Levodopa |
| PD03/M/75 | 2007 | 02/2011 | 1 | Ropinirole |
| PD04/M/64 | 2000 | 07/2011 | 3 | Levodopa, Amantadine, Pramipexole, Rasagiline |
| PD05/M/67 | 2007 | 07/2011 | 1 | Levodopa, Ropinirole, Rasagiline |
| PD06/M/51 | 2010 | 09/2011 | 2 | Levodopa, Rasagiline |
| PD07/F/62 | 2007 | 10/2011 | 3 | Levodopa, Rasagiline, Piribedil |
| PD08/M/38 | 2010 | 10/2011 | 2 | Pramipexole |
| PD09/M/78 | 2007 | 12/2011 | 3 | Levodopa |
| PD10/F/82 | 2001 | 12/2011 | 3 | Levodopa, Amantadine, Ropinirole |
| PD11/F/68 | 2000 | 12/2011 | 3 | Levodopa, Amantadine, Pramipexole |
| HC01/F/58 | 08/2010 | |||
| HC02/M/71 | 08/2010 | |||
| HC03/F/53 | 02/2011 | |||
| HC04/F/63 | 02/2011 | |||
| HC05/M/73 | 03/2011 | |||
| HC06/F/64 | 03/2011 | |||
| HC07/F/69 | 03/2011 | |||
| HC08/F/74 | 09/2011 | |||
| HC09/M/85 | 12/2011 | |||
| HC10/M/73 | 12/2011 |
PSP, progressive supranuclear palsy; PD, Parkinson's disease; HC, healthy controls; DD, disease duration; H&Y, Hoehn and Yahr Stage. H&Y stage is significantly different between PD and PSP [t(19) = 4.12, p < 0.001]; real-life measurement duration differs significantly between PSP and HC (p = 0.02 post-hoc test); all other comparisons do not show a significant difference (p > 0.05).